UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Sanaz Memarzadeh, MD, PhD, discusses a combination regimen of birinapant and carboplatin in patients with high-grade serous ovarian cancers and high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA-125–negative cells.

Dennis Slamon, MD, PhD, discusses the inhibition of CDK 4/6 and PD-1, which represent two of the most exciting developments in the field of metastatic breast cancer.

OncLive's editorial and marketing groups will spread the news about the center's community outreach and research programs.

PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.

The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced NSCLC across all histologies whose disease has progressed on or after platinum-containing chemotherapy, as well as a targeted agent in EGFR- or ALK-positive patients.

Dennis J. Slamon, MD, PhD, has had an immeasurable impact on the treatment of women with breast cancer by developing trastuzumab (Herceptin) and helping to launch the era of targeted therapies. He was honored in the Breast Cancer category with a 2014 Giants of Cancer Careâ„¢ award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.

For further insight on the significance of palbociclib's approval, OncLive sat down with the lead investigator of PALOMA-1, Richard Finn, MD, from the Jonsson Comprehensive Cancer Center at UCLA.

Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.

To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.

Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.

Head and neck cancer patients who participated in a swallow preservation protocol were less likely to suffer from the detrimental effects associated with dysphagia, a common complication associated with radiation therapy and chemoradiation therapy.

Delivering high-quality cancer care continues to be a daunting problem for the US healthcare system because of a combination of factors, including an aging population, a shrinking work force, the rising cost of therapies, and a complex disease state and treatment regimen.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

The investigational antibody lambrolizumab demonstrated significant antitumor activity and good response rates as well as a tolerable toxicity profile in patients with melanoma.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses the efficacy of ipilimumab for the treatment of melanoma.

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

Antoni Ribas, MD, from the UCLA Jonsson Comprehensive Cancer Center, discusses a phase I/II trial combining vemurafenib and ipilimumab for metastatic melanoma.

Dr. Antoni Ribas, from UCLA Jonsson Comprehensive Cancer Center, on the Benefits of MAPK Inhibition With Dabrafenib and Trametinib

The molecular basis behind the relatively high incidence of secondary skin cancers after patients received vemurafenib has been discovered.

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates and durable treatment responses.

The past decade has brought a significant increase in attention to the role that food and nutrients might play in fighting cancer.

A dendritic cell vaccine under development may increase median survival time in patients with glioblastoma

Plenty of children are afraid to go to the doctor. Dennis Slamon used to look forward to it.